| First Author | Fu Y | Year | 2015 |
| Journal | Sci Rep | Volume | 5 |
| Pages | 13347 | PubMed ID | 26289340 |
| Mgi Jnum | J:254087 | Mgi Id | MGI:6101867 |
| Doi | 10.1038/srep13347 | Citation | Fu Y, et al. (2015) Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci Rep 5:13347 |
| abstractText | Salivary duct carcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate. Herein, we reported the detection of somatic KRAS A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid SDC variants. Transgenic mice carrying the human oncogenic KRAS(G12V), which spatiotemporal activation by tamoxifen (TAM)-inducible Cre recombinase Ela-CreERT in the submandibular gland (SMG) ductal cells, was established and characterized. Visible carcinoma was detected as early as day-15 following oncogenic KRAS(G12V) induction alone, and these tumors proliferate rapidly with a median survival of 28-days accompanied with histological reminiscences to human sarcomatoid SDC variants. Moreover, these tumors were resistant to cetuximab treatment despite augmented EGFR signaling, attesting its malignancy. Our findings suggest that LGL-KRas(G12V);Ela-CreERT transgenic mice could serve as a useful preclinical model for investigating underlying mechanisms and developing potential therapies. |
